The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
microRNA Therapeutics in Cancer — An Emerging Concept
Open accessAbstract
MicroRNAs (miRNAs) are an evolutionarily conserved class of small, regulatory non-coding RNAs that negatively regulate protein coding gene and other non-coding transcripts expression. miRNAs have been established as master regulators of cellular processes, and they play a vital role in tumor initiation, progression and metastasis. Further, widespread deregulation of microRNAs have been reported in several cancers, with several microRNAs playing oncogenic and tumor suppressive roles. Based on these, miRNAs have emerged as promising therapeutic tools for cancer management. In this review, we have focused on the roles of miRNAs in tumorigenesis, the miRNA-based therapeutic strategies currently being evaluated for use in cancer, and the advantages and current challenges to their use in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Xiao, J., Yang, B., Lin, H., Lu, Y., Luo, X., & Wang, Z. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21062 · Cited by 193
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Self-citation(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
Self-citationSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Cited by
An overview of microRNAs: Biology, functions, therapeutics, and analysis methods
Saliminejad, K., Khorram Khorshid, H. R., Soleymani Fard, S., & Ghaffari, S. H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27486 · Cited by 1,872
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X., & Zhu, J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0719-3 · Cited by 517
MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance
Iqbal, M. A., Arora, S., Prakasam, G., Calin, G. A., & Syed, M. A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.003 · Cited by 449
Self-citationClustered miRNAs and their role in biological functions and diseases
Kabekkodu, S. P., Shukla, V., Varghese, V. K., D' Souza, J., Chakrabarty, S., & Satyamoorthy, K. (2018) · Biological Reviews · doi:10.1111/brv.12428 · Cited by 358
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
Epidrugs: targeting epigenetic marks in cancer treatment
Miranda Furtado, C. L., Dos Santos Luciano, M. C., Silva Santos, R. D., Furtado, G. P., Moraes, M. O., & Pessoa, C. (2019) · Epigenetics · doi:10.1080/15592294.2019.1640546 · Cited by 345
The Regulatory Role of MicroRNAs in Breast Cancer
Loh, H.-Y., Norman, B. P., Lai, K.-S., Rahman, N. M. A. N. A., Alitheen, N. B. M., & Osman, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194940 · Cited by 326
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
Scioli, M. G., Storti, G., D’Amico, F., Rodríguez Guzmán, R., Centofanti, F., Doldo, E., Céspedes Miranda, E. M., & Orlandi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061995 · Cited by 281
Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors
Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Bibaki, E., Tsitoura, E., Vasarmidi, E., Margaritopoulos, G., Trachalaki, A., Koutoulaki, C., Georgopoulou, T., Spandidos, D., Tzanakis, N., & Antoniou, K. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8778 · Cited by 29
Metadata
- Authors
- Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 12
- Pages
- 34-42
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2521569068
- Cited by
- 453
- References
- 93
- FWCI
- 20.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.